SCHEMBL3969749

SCHEMBL3969749

[CH2]Oc1cccc2[nH]c(C(F)F)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
POLB P06746 2/20 0.49
PARP1 P09874 6/20 0.35
CBFB Q13951 2/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
GAA P10253 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MAOB P27338 1/20 0.32
ADORA2A P29274 1/20 0.32
MGAM O43451 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
DRD2 P14416 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3969023 0.84 HSD17B10 (0.44) ALDH1A1PARP1CBFBTP53CYP3A4
SCHEMBL31157033 0.84 ALDH1A1 (0.50) ALDH1A1POLBPARP1CBFBTP53
SCHEMBL477289 0.84 ALDH1A1 (0.50) ALDH1A1POLBPARP1CBFBTP53
SCHEMBL909787 0.80 CBFB (0.54) ALDH1A1POLBPARP1CBFBTP53
SCHEMBL3974683 0.78 POLB (0.53) ALDH1A1POLBPARP1HPGDHSD17B10
SCHEMBL6526190 0.78 PDE5A (0.45) ALDH1A1POLBPARP1CBFBDRD2
SCHEMBL2812508 0.77 ALDH1A1 (0.42) ALDH1A1POLBPARP1CBFBTP53
SCHEMBL13164363 0.77 PDE5A (0.46) ALDH1A1POLBCBFBDRD2DRD4
SCHEMBL13164371 0.75 CYP1A2 (0.48) ALDH1A1POLBCBFBCYP2C19KDM4E
SCHEMBL3967676 0.75 NPC1 (0.46) ALDH1A1PARP1CBFBTP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 ALDH1A1 839/4885POLB 1914/4885PARP1 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.